Literature DB >> 8549424

Transgenic systems in studying myelin gene expression.

K Ikenaka1, T Kagawa.   

Abstract

The myelin sheath is produced by oligodendrocytes in the central nervous system (CNS) and Schwann cells in the peripheral nervous system (PNS). It is necessary to introduce DNA into these cells to study gene regulation and the functions of myelin proteins. Since these cells are labile to commonly used techniques to introduce DNA, a transgenic system must be used for these studies. Myelin basic protein (MBP) and myelin proteolipid protein (PLP) are both highly abundant in CNS myelin, but are also produced in Schwann cells. Various lengths (6.5 kb to 256 bp) of the promoter region of the (classic) MBP gene directed oligodendrocyte-specific expression of the reporter gene in transgenic mice, but no expression was seen in Schwann cells. Promoter regions of the PLP gene (4.2-2.4 kb) seem to contain all the information required for correct spatiotemporal expression, but the level of expression was low. The first intron of the PLP gene is a candidate for the location of the enhancer-like element. Studies on MBP mutant mice carrying wild-type MBP gene or cDNA clearly demonstrated that one function of MBP is to make myelin lamellae compact by fusing the cytoplasmic surfaces of oligodendrocytes into the form of major dense lines. However, functional analysis of PLP gene products using a similar strategy produced confusing results. The wild-type PLP gene introduced into jimpy mutant mice (one of the PLP mutants) did not complement the mutant phenotype. Moreover, overexpression of the PLP gene itself (in wild-type background) was shown to produce a phenotype similar to that of the mutants, including arrest in oligodendrocyte maturation and hypomyelination. Thus, PLP gene products play a fundamental role in oligodendrocyte maturation as well as in the stabilization of myelin structure, and its expression must be tightly regulated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8549424     DOI: 10.1159/000111281

Source DB:  PubMed          Journal:  Dev Neurosci        ISSN: 0378-5866            Impact factor:   2.984


  9 in total

1.  A transgenic mouse model for inducible and reversible dysmyelination.

Authors:  C Mathis; C Hindelang; M LeMeur; E Borrelli
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Genomic rearrangements resulting in PLP1 deletion occur by nonhomologous end joining and cause different dysmyelinating phenotypes in males and females.

Authors:  Ken Inoue; Hitoshi Osaka; Virginia C Thurston; Joe T R Clarke; Akira Yoneyama; Lisa Rosenbarker; Thomas D Bird; M E Hodes; Lisa G Shaffer; James R Lupski
Journal:  Am J Hum Genet       Date:  2002-09-20       Impact factor: 11.025

Review 3.  Glial grafting for demyelinating disease.

Authors:  V Tepavcević; W F Blakemore
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

4.  On the occurrence of hypomyelination in a transgenic mouse model: a consequence of the myelin basic protein promoter?

Authors:  Stefanie Gaupp; Joseph Arezzo; Dipankar J Dutta; Gareth R John; Cedric S Raine
Journal:  J Neuropathol Exp Neurol       Date:  2011-12       Impact factor: 3.685

5.  The evolution of lipophilin genes from invertebrates to tetrapods: DM-20 cannot replace proteolipid protein in CNS myelin.

Authors:  B Stecca; C M Southwood; A Gragerov; K A Kelley; V L Friedrich; A Gow
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

6.  Phosphodiesterase I, a novel adhesion molecule and/or cytokine involved in oligodendrocyte function.

Authors:  B Fuss; H Baba; T Phan; V K Tuohy; W B Macklin
Journal:  J Neurosci       Date:  1997-12-01       Impact factor: 6.167

7.  The unfolded protein response modulates disease severity in Pelizaeus-Merzbacher disease.

Authors:  Cherie M Southwood; James Garbern; Wei Jiang; Alexander Gow
Journal:  Neuron       Date:  2002-11-14       Impact factor: 17.173

8.  Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease.

Authors:  A Gow; C M Southwood; R A Lazzarini
Journal:  J Cell Biol       Date:  1998-02-23       Impact factor: 10.539

9.  Usefulness of a mouse myelin basic protein promoter for gene therapy of malignant glioma: myelin basic protein promoter is strongly active in human malignant glioma cells.

Authors:  Y Miyao; K Shimizu; M Tamura; H Akita; K Ikeda; E Mabuchi; H Kishima; T Hayakawa; K Ikenaka
Journal:  Jpn J Cancer Res       Date:  1997-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.